Study of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell Malignancies
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- 45
Summary
- Conditions
- Phase I: Relapsed or Refractory B-cell Malignancies
- Phase II Cohort A: Relapsed or Refractory Mantle Cell Lymphoma
- Phase II Cohort B: Relapsed or Refractory Chronic Lymphocytic Leukemia
- Type
- Interventional
- Phase
- Phase 1Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 130 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT03932331
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Jun Zhu, Prof Beijing Cancer Hospital
Get Well Soon